DK0726954T4 - CNTF-familie-antagonister - Google Patents

CNTF-familie-antagonister

Info

Publication number
DK0726954T4
DK0726954T4 DK94930818T DK94930818T DK0726954T4 DK 0726954 T4 DK0726954 T4 DK 0726954T4 DK 94930818 T DK94930818 T DK 94930818T DK 94930818 T DK94930818 T DK 94930818T DK 0726954 T4 DK0726954 T4 DK 0726954T4
Authority
DK
Denmark
Prior art keywords
cntf
family antagonists
cntf family
receptor component
antagonists
Prior art date
Application number
DK94930818T
Other languages
Danish (da)
English (en)
Other versions
DK0726954T3 (da
Inventor
Neil Stahl
Aris Economides
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22490270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0726954(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of DK0726954T3 publication Critical patent/DK0726954T3/da
Application granted granted Critical
Publication of DK0726954T4 publication Critical patent/DK0726954T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK94930818T 1993-10-20 1994-10-19 CNTF-familie-antagonister DK0726954T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/140,222 US5470952A (en) 1993-10-20 1993-10-20 CNTF and IL-6 antagonists
PCT/US1994/011873 WO1995011303A1 (fr) 1993-10-20 1994-10-19 Antagonistes de la famille cntf

Publications (2)

Publication Number Publication Date
DK0726954T3 DK0726954T3 (da) 2000-05-01
DK0726954T4 true DK0726954T4 (da) 2007-10-01

Family

ID=22490270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94930818T DK0726954T4 (da) 1993-10-20 1994-10-19 CNTF-familie-antagonister

Country Status (15)

Country Link
US (2) US5470952A (fr)
EP (1) EP0726954B2 (fr)
JP (1) JP3961562B2 (fr)
CN (1) CN1138350A (fr)
AT (1) ATE187982T1 (fr)
AU (1) AU679579B2 (fr)
CA (1) CA2173846C (fr)
DE (1) DE69422304T3 (fr)
DK (1) DK0726954T4 (fr)
ES (1) ES2139759T5 (fr)
GR (1) GR3032777T3 (fr)
IL (1) IL111324A0 (fr)
PT (1) PT726954E (fr)
WO (1) WO1995011303A1 (fr)
ZA (1) ZA948242B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
CA2147466A1 (fr) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Antagonistes du recepteur de l'interleukine-6
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
AUPN024994A0 (en) * 1994-12-23 1995-01-27 Ludwig Institute For Cancer Research Assay and peptides for use therein
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
SE9701010D0 (sv) 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
ATE272114T1 (de) 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18
US6410245B1 (en) * 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6864359B1 (en) * 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
DE60041393D1 (de) * 1999-03-11 2009-03-05 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis
US6682739B1 (en) * 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
WO2001016166A2 (fr) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides comprenant des domaines de recepteur d'interleukine-6 se liant a un ligand, acides nucleiques correspondants, anticorps, compositions, et leurs procedes d'utilisation
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
WO2002064021A2 (fr) * 2001-02-12 2002-08-22 Baylor College Of Medicine Procedes et compositions pour reguler la formation osseuse par modulation de l'activite ciliaire du facteur neurotrophique
US6864047B2 (en) * 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
WO2002088733A1 (fr) * 2001-04-23 2002-11-07 Eiken Kagaku Kabushiki Kaisha Methode d'analyse faisant intervenir une interaction intermoleculaire par rapporteur (marqueur)
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1421189A2 (fr) * 2001-08-22 2004-05-26 Helix Biopharma Corp. Procede et dispositif destines a l'expression, la purification et la detection proteiques
US20060165683A1 (en) 2001-12-05 2006-07-27 Gerard Karsenty Methods and compositions for control of bone formation via modulation of sympathetic tone
MXPA05002219A (es) 2002-08-28 2005-07-05 Immunex Corp Composiciones y metodos para tratar una enfermedad cardiovascular.
WO2004037209A2 (fr) * 2002-10-25 2004-05-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methodes pouvant empecher la recurrence d'une tumeur par blocage de tgf-?
FI20031050L (fi) * 2003-07-09 2005-01-10 Valtion Teknillinen Menetelmä proteiinien katkaisuun
US20050069987A1 (en) * 2003-09-30 2005-03-31 Daly Thomas J. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005047337A1 (fr) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. Composition pharmaceutique presentant une region de l'immunoglobuline fc comme excipient
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007061981A2 (fr) 2005-11-21 2007-05-31 Lumera Corporation Detecteur a resonance de plasmon en surface avec mecanisme de balayage d’angle entraine par actionneur
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
TWI381850B (zh) * 2005-12-30 2013-01-11 Pharmaessentia Corp 藥物與聚合物之共軛物
CA2657581A1 (fr) 2006-07-11 2008-01-17 Roy C. Levitt Prevention de la rhinosinusite et therapie avec des inhibiteurs de cytokine proinflammatoires
US8940683B2 (en) 2006-08-10 2015-01-27 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
EP2574671B1 (fr) 2007-03-19 2016-02-03 National Research Council Of Canada Antagonistes de ligands et leurs utilisations
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (fr) * 2008-09-17 2010-03-25 National Research Council Of Canada Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf-β
EP3929206A1 (fr) 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Analogues de la compstatine à longue durée d'action et compositions et méthodes associées
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
CA3287719A1 (en) 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
CA3059731A1 (fr) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Molecule recepteur d'il4/il13 a usage veterinaire
BR112019023071A2 (pt) 2017-05-04 2020-06-09 Acceleron Pharma Inc proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
EP3870601A4 (fr) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. Molécule du récepteur d'il4/il13 à usage vétérinaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (fr) * 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3255699B2 (ja) * 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists

Also Published As

Publication number Publication date
JP3961562B2 (ja) 2007-08-22
DE69422304D1 (de) 2000-01-27
EP0726954A1 (fr) 1996-08-21
EP0726954B2 (fr) 2007-05-30
DK0726954T3 (da) 2000-05-01
HK1008346A1 (en) 1999-05-07
CN1138350A (zh) 1996-12-18
GR3032777T3 (en) 2000-06-30
WO1995011303A1 (fr) 1995-04-27
CA2173846C (fr) 2009-01-27
ZA948242B (en) 1995-06-13
US5470952A (en) 1995-11-28
AU7982794A (en) 1995-05-08
IL111324A0 (en) 1994-12-29
PT726954E (pt) 2000-04-28
CA2173846A1 (fr) 1995-04-27
ES2139759T5 (es) 2007-11-16
JPH09504030A (ja) 1997-04-22
ES2139759T3 (es) 2000-02-16
ATE187982T1 (de) 2000-01-15
AU679579B2 (en) 1997-07-03
EP0726954B1 (fr) 1999-12-22
US5844099A (en) 1998-12-01
DE69422304T3 (de) 2007-12-27
DE69422304T2 (de) 2000-05-11

Similar Documents

Publication Publication Date Title
DK0726954T3 (da) CNTF-familie-antagonister
ATE309375T1 (de) Onkostatin- m rezeptor
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
NO952398D0 (no) Pyrrolpyrimidiner som CRF antagonister
EP0667773A4 (fr) Antagonistes des recepteurs du fibrinogene.
ATE205711T1 (de) Endothelin-rezeptor-antagonisten
FI941178L (fi) 5-HT4-reseptoriantagonisteja
FI933253A7 (fi) Uusia amyliiniantagonistipeptidejä ja käyttö amyliiniantagonisteina
GR1001129B (el) Ανταγωνιστες ccκ αναλογου αμινοξεος.
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
MX9203074A (es) 4-(1h-pirrol-1-il)-imidazoles con actividad antagonista de angiotensina ii.
RU94044322A (ru) Замещенные в кольце z-амино-1,2,3,4-тетрагидронафталины и 3-аминохроманы
NO991926L (no) Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksin-reseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer
DK0556171T3 (da) Væksthormon-antagonister
IT8848075A0 (it) Anello di regolazione adatto all'uso di frizioni con compensazione dell'usura manuali e automatiche
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.
DK111091D0 (da) Hovedtelefonsaet samt anvendelse heraf
DE69203803D1 (de) Abstandselement als zusatz zu dübelverankerungsvorrichtungen für wandbekleidungsplatten.
DE69004455D1 (de) Alpha-adrenergene Rezeptor-Antagonisten.
FI960882L (fi) Alternaria alternata -yhdistelmäallergeeneja
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
MX9203582A (es) Peptidos y composiciones farmaceuticas con actividad agonista y antagonista de la hormona de glicoproteina.
MX9204795A (es) 1-fenil-1-benzoilamino-5-aminopentanos substituidos su preparacion y uso.
ITGE960010A0 (it) Utilizzo con impasti bituminosi e cementizi di ceneri tossico-nocive e ceneri normali.